Skip to main
GMED
GMED logo

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical has potential upside drivers that may enhance its financial performance, including faster-than-expected growth in the spine market, increased sales from Enabling Technologies, and improved profit margins. Despite reported base business results of $651 million in 2Q25, reflecting a 3.3% increase, the company faced challenges with a consensus estimate of $664 million. The overall outlook remains positive, with more fundamental elements supporting growth prospects despite the recent results falling short of expectations.

Bears say

Globus Medical Inc. faces significant risks that contribute to a negative outlook, including anticipated slower growth in the spine market and potential revenue dis-synergies resulting from the NUVA merger. Furthermore, projections indicate that revenue growth may decelerate to low-single digits, which could restrict margin expansion and impact overall financial performance. In addition, weaker sales in the Enabling Technologies segment have raised concerns regarding the company's growth trajectory, as reflected in organic guidance that appears softer than expected following the recent quarter.

Globus Medical (GMED) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 11 analysts, Globus Medical (GMED) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.